Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-06-04
2009-11-17
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387100
Reexamination Certificate
active
07618628
ABSTRACT:
CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5219728 (1993-06-01), Khayat et al.
patent: 5399493 (1995-03-01), Emerson et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5455030 (1995-10-01), Ladner et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5641863 (1997-06-01), Schreiber et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5837821 (1998-11-01), Wu
patent: 5976831 (1999-11-01), Peltz et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025158 (2000-02-01), Gonzalez et al.
patent: 6103889 (2000-08-01), Whitlow et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6207804 (2001-03-01), Huston et al.
patent: 6277375 (2001-08-01), Ward
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6737056 (2004-05-01), Presta
patent: 2004/0010124 (2004-01-01), Johnson et al.
patent: 2007/0036786 (2007-02-01), Tuaillon et al.
patent: 0753 065 (1997-01-01), None
patent: 343 950 (2000-10-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/061090 (2002-08-01), None
Alegre, M-L et al. (Jun. 1, 1992). “Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a ‘Humanized’ OKT3 Monoclonal Antibody,”J. Immunol. 148(11):3461-3468.
Altschul S.F. et al. (1990). “Basic Local Alignment Search Tool,”J. Mol. Biol. 215:403-410.
Amit et al.Science1986. 233:747-753.
Anonymous (Dec. 20, 2000). “PerCP Mouse Anti-Human Monoclonal Antibody,” PharMingen Technical Data Sheet, CD3/CD16/CD45, 2 pages.
Anonymous (Jun. 6, 2001). “R-Phycoerythrin (R-PE)-Conjugated Mouse Anti-Human Monoclonal Antibody,” BD PharMingen Technical Data Sheet., CD16, one page.
Barbas, III, C.F. et al. (Sep. 1991). “Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site,”PNAS88:7978-7982.
Bedzyk, W.D. et al. (Jan. 25, 1989). “Comparison of Variable Region Primary Structures Within Anti-Fluorescein Idiotype Family,”J. Biol. Chem. 264(3):1565-1569.
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Boder, E.T. et al. (Jun. 1997). “Yeast Surface Display for Screening Combinatorial Polypeptide Libraries,”Nature Biotechnology15:553-557.
Boder, E.T. et al. (Sep. 26, 2000). “Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen-Binding Affinity,”PNAS. 97(20):10701-10705.
Bolland, S. et al. (1999). “Inhibitory Pathways Triggered by ITIM-Containing Receptors,”Adv. In Immunol. 72:149-177.
Bolt et al., 1993, “The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties,”Eur. J. Immunol. 23(2):403-11.
Brummell et al. Biochemistry. 1993. 32;4:1180-1187.
Brussel, J. et al. (1988). “Infusion of a Monoclonal Anti-FcRIII in Patients with Refractory ITP,”Neo-Adjuvant Chemotherapy169:883-887.
Brussel et al., 2000, “Fc receptor blockade and immune thrombocytopenic purpura,” Semin. Hematol. 37(3):261-6.
Canfield, S.M. et al. (1991). “The Binding Affinity of Human IgG for Its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by Hinge Region,”J. Exp. Med. 173:1483-1491.
Carter, P. et al. (1992). “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment,”Bio/Technology10:163-167.
Carton et al.,“Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in 1gG Fc receptor FcyRIlla gene.”BloodFeb. 1, 2002; 99(3):754-8.
Casali, P. et al. (1986). “Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV,”Science234:476-552.
Cassatella et al., 1989, “Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes,”J. Exp. Med. 169(2):549-67.
Cheung, R.C. et al. (1990). “Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,”Virology176:546-552.
Chothia, C. et al. (Dec. 1989). “Conformation of Immunoglobulin Hypervariable Regions,”Nature342:877-883.
Clarkson, S.B. et al. (Aug. 1986). “Blockade of Clearance of Immune Complexes by an Anti-Fcy Receptor Monoclonal Antibody,”J. Exp. Med. 164:474-489.
Clarkson, S.B. et al. (1986). “Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcy-Receptor Antibody,”N. Engl. J. Med. 314(19):1236-1239.
Clynes et al., “Uncoupling of immune complex formation and kidney damage in autoimmuneglomerulonephritis.”ScienceFeb. 13, 1998;279(5353):1052-1054.
Clynes, R.A. et al. (Apr. 2000). “Inhibitory Fc Receptors Modulate In Vivo Cytoxicity Against Tumor Targets,”Nat. Med. 6(4):443-446.
Co, M.S. et al. (Apr. 1991). “Humanized Antibodies for Antiviral Therapy,”PNAS88:2869-2873.
Daugherty, P.S. et al. (1998). “Antibody Affinity Maturation Using Macterial Surface Display,”Protein Enginee. 11(9):825-832.
Ding, Y.-H. et al. (Apr. 1998). “Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Accids,” Immunity 8:403-411.
Duncan, A.R. et al. (1988). “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG,”Nature332:563-564.
Edberg JC, Kimberly RP., “Cell type-specific glycoforms of Fc gamma RIlla (CD16): differential ligand binding.”J Immunol. Oct. 15, 1997; 159(8):3849-3857.
Edge, J.C. et al. (1997). “Cell Type-Specific Glycoforms of FcγRIlla (CD16): Differential Ligand Binding,”J. Immunol. 159(8):3849-3857.
Farag, S.F. et al., “FcyRIlla and FcyRIlla Polymorphisms Do Not Predict Response to Rituximad in B-Cell Chronic Lymphocytic Leukemia.”BloodFeb. 15, 2004; 103(4):1472-4; pre-published online Oct. 16, 2003.
Fijen et al. “The role of Fcγrecptor polymorphisms and C3 in the immune defense against Neisseria meningitidis in complement-deficient individuals.”Clin Exp Immunol. May 2000; 120(2): 338-45.
Fleit, H.B. et al. (May 1982). “Human Neutrophil Fcγ Receptor Distribution and Structure,”PNAS79:3275-3279.
Foote, J. et al. (1992). “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol. 224:487-499.
Frank et al., “Defective reticuloendothelial system Fc-recptor function in systemic lupus erythematosus.”N Engl J Med. Mar. 8, 1979; 300(10): 518-523.
Friend, P.J. et al. (1999). “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection,”Transplantation68(11):1632-1637.
Fujiwara et al., “Determination of granulocyte-specific antigens on neutrophil FcA recptor Illb by PC-preferential homoduplex formation assay, and gene frequencies in the Japanese population.”Vox Sang. 1999; 77(4):218-22.
Hibbs et al. “Membrane-proximal Ig-like domain of Fc gamma RIII (CD16) contains residues critical for ligand binding.”J Immunol. May 1, 1994; 152(9):4466-4474.
Hoogenboom, H.R. And Winter, G. (1991). “By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,&#
Huang Ling
Johnson Leslie S.
Li Hua
Tuaillon Nadine
Brivanlou Margaret B.
Enmon, Jr. Richard M.
King & Spalding LLP
Macrogenics Inc.
Ouspenski Ilia
LandOfFree
CD16A binding proteins and use for the treatment of immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD16A binding proteins and use for the treatment of immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD16A binding proteins and use for the treatment of immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111614